Rapid Microfluidic Preparation of Niosomes for Targeted Drug Delivery.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Sep 2019
Historique:
received: 08 08 2019
revised: 16 09 2019
accepted: 20 09 2019
entrez: 25 9 2019
pubmed: 25 9 2019
medline: 15 2 2020
Statut: epublish

Résumé

Niosomes are non-ionic surfactant-based vesicles with high promise for drug delivery applications. They can be rapidly prepared via microfluidics, allowing their reproducible production without the need of a subsequent size reduction step, by controlled mixing of two miscible phases of an organic (lipids dissolved in alcohol) and an aqueous solution in a microchannel. The control of niosome properties and the implementation of more complex functions, however, thus far are largely unknown for this method. Here we investigate microfluidics-based manufacturing of topotecan (TPT)-loaded polyethylene glycolated niosomes (PEGNIO). The flow rate ratio of the organic and aqueous phases was varied and optimized. Furthermore, the surface of TPT-loaded PEGNIO was modified with a tumor homing and penetrating peptide (tLyp-1). The designed nanoparticular drug delivery system composed of PEGNIO-TPT-tLyp-1 was fabricated for the first time via microfluidics in this study. The physicochemical properties were determined through dynamic light scattering (DLS) and zeta potential analysis. In vitro studies of the obtained formulations were performed on human glioblastoma (U87) cells. The results clearly indicated that tLyp-1-functionalized TPT-loaded niosomes could significantly improve anti-glioma treatment.

Identifiants

pubmed: 31546717
pii: ijms20194696
doi: 10.3390/ijms20194696
pmc: PMC6801367
pii:
doi:

Substances chimiques

Drug Carriers 0
Liposomes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Int J Pharm. 2017 Apr 15;521(1-2):54-60
pubmed: 28163227
Adv Colloid Interface Sci. 2012 Nov 15;183-184:46-54
pubmed: 22947187
Biochem Pharmacol. 2007 Nov 15;74(10):1437-44
pubmed: 17540344
PLoS One. 2015 Sep 23;10(9):e0137676
pubmed: 26398657
Cancer Chemother Pharmacol. 1995;36(5):393-403
pubmed: 7634381
Biomaterials. 2013 Jul;34(22):5640-50
pubmed: 23639530
Oncotarget. 2018 Dec 14;9(98):37252-37267
pubmed: 30647857
J Control Release. 2004 May 18;96(3):449-61
pubmed: 15120901
Adv Mater. 2012 Jul 24;24(28):3747-56
pubmed: 22550056
Oncotarget. 2017 Jun 27;8(43):74019-74035
pubmed: 29088765
Sci Rep. 2016 May 19;6:25876
pubmed: 27194474
Pharmaceutics. 2019 Mar 16;11(3):null
pubmed: 30884782
Int J Pharm. 2016 Nov 30;514(1):160-168
pubmed: 27863660
Lab Chip. 2017 Jan 17;17(2):209-226
pubmed: 27991629
Expert Rev Anticancer Ther. 2008 May;8(5):819-31
pubmed: 18471053
Exp Mol Pathol. 2009 Jun;86(3):215-23
pubmed: 19186176
PLoS One. 2013 Nov 26;8(11):e81815
pubmed: 24303074
Nano Lett. 2008 Sep;8(9):2906-12
pubmed: 18656990
Biomaterials. 2015 Jun;52:335-46
pubmed: 25818440
Int J Pharm. 2013 Dec 15;458(1):224-9
pubmed: 24060370
J Biol Chem. 1985 Nov 25;260(27):14873-8
pubmed: 2997227
J Control Release. 2014 Jul 10;185:22-36
pubmed: 24747765
Biomater Sci. 2019 Jan 29;7(2):461-471
pubmed: 30656305
Eur J Pharm Biopharm. 2011 Sep;79(1):189-96
pubmed: 21352915
Drug Dev Ind Pharm. 2008 Jan;34(1):10-23
pubmed: 18214751
J Biomed Nanotechnol. 2013 Apr;9(4):559-63
pubmed: 23621014
ACS Nano. 2015 Jul 28;9(7):6706-16
pubmed: 26042619
J Pept Sci. 2019 Mar;25(3):e3145
pubmed: 30588706
J Control Release. 2010 Jan 4;141(1):13-21
pubmed: 19686789
Langmuir. 2013 Oct 15;29(41):12638-46
pubmed: 24040748
AAPS PharmSciTech. 2009;10(4):1186-92
pubmed: 19856107
Oncogene. 2012 Aug 16;31(33):3754-63
pubmed: 22179825
Drug Deliv. 2016 Oct;23(8):2827-2837
pubmed: 26548664
J Pharm Pharmacol. 2017 Oct;69(10):1318-1326
pubmed: 28703281
Adv Colloid Interface Sci. 2014 Mar;205:187-206
pubmed: 24369107
Toxicol Res (Camb). 2015 Aug 7;5(1):126-135
pubmed: 30090332
Int J Pharm. 2014 Dec 30;477(1-2):361-8
pubmed: 25455778
Arch Pharm Res. 2005 May;28(5):626-35
pubmed: 15974453
Int J Mol Sci. 2017 Jul 02;18(7):null
pubmed: 28671589
AAPS PharmSciTech. 2007 Dec 14;8(4):E106
pubmed: 18181527
J Photochem Photobiol B. 2016 Dec;165:182-188
pubmed: 27816641
Langmuir. 2012 Feb 21;28(7):3633-40
pubmed: 22268499
Int J Pharm. 2017 Jan 10;516(1-2):52-60
pubmed: 27836752
Biomaterials. 2013 Jan;34(4):1135-45
pubmed: 23146434

Auteurs

Didem Ag Seleci (D)

Institute for Particle Technology (iPAT), Technische Universität Braunschweig, 38104 Braunschweig, Germany. d.ag-seleci@tu-braunschweig.de.
Centre for Pharmaceutical Engineering Research (PVZ), Technische Universität Braunschweig, 38106 Braunschweig, Germany. d.ag-seleci@tu-braunschweig.de.

Viktor Maurer (V)

Institute for Particle Technology (iPAT), Technische Universität Braunschweig, 38104 Braunschweig, Germany. v.maurer@tu-braunschweig.de.
Centre for Pharmaceutical Engineering Research (PVZ), Technische Universität Braunschweig, 38106 Braunschweig, Germany. v.maurer@tu-braunschweig.de.

Frank Stahl (F)

Institute for Technical Chemistry, Leibniz University Hannover, 30167 Hannover, Germany. stahl@iftc.uni-hannover.de.

Thomas Scheper (T)

Institute for Technical Chemistry, Leibniz University Hannover, 30167 Hannover, Germany. scheper@iftc.uni-hannover.de.

Georg Garnweitner (G)

Institute for Particle Technology (iPAT), Technische Universität Braunschweig, 38104 Braunschweig, Germany. g.garnweitner@tu-braunschweig.de.
Centre for Pharmaceutical Engineering Research (PVZ), Technische Universität Braunschweig, 38106 Braunschweig, Germany. g.garnweitner@tu-braunschweig.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH